Oravax To Develop Israeli Oral COVID-19 Vaccine in Mexico
Israel’s Oravax Medical, a subsidiary of Oramed Pharmaceuticals Inc. announced this month that it has partnered with Genomma Lab Internacional, in a 50/50 joint venture to develop and commercialize Oravax’s oral COVID-19 vaccine candidate in Mexico.
The Mexico-based pharmaceutical firm Genomma Lab is expected to contribute its sales and distribution network to the joint venture’s oral COVID-19 vaccine development, as well as clinical, regulatory, and commercial activities in Mexico supported by close strategic cooperation between the two companies. Genomma Lab will leverage its extensive supply chain capabilities, partnerships, and market presence in Latin America to support the business development process and vaccine roll-out throughout the region.
Photo courtesy of